AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties

@article{Kalatskaya2009AMD3100IA,
  title={AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties},
  author={Irina Kalatskaya and Yamina A Berchiche and St{\'e}phanie Gravel and Brian J. Limberg and Jan S. Rosenbaum and Nikolaus Heveker},
  journal={Molecular Pharmacology},
  year={2009},
  volume={75},
  pages={1240 - 1247}
}
The bicyclam AMD3100 is known as a small synthetic inhibitor of the CXCL12-binding chemokine receptor CXCR4. Here, we show that AMD3100 also binds to the alternative CXCL12 receptor CXCR7. CXCL12 or AMD3100 alone activate β-arrestin recruitment to CXCR7, which we identify as a previously unreported signaling pathway of CXCR7. In addition, AMD3100 increases CXCL12 binding to CXCR7 and CXCL12-induced conformational rearrangements in the receptor dimer as measured by bioluminescence resonance… 
The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
TLDR
Qualitative bioluminescence resonance energy transfer finds that the CXCR7 receptor core formed by the seven-transmembrane domains and the connecting loops determines the agonistic activity of both TC14012 and AMD3100.
CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.
TLDR
CXCR7, when up-regulated upon inflammation, can act as a negative regulator of CXCR4 by heterodimerizing with CX CR4, inducing its internalization and degradation, and suggests that CxCR7 agonists can have a therapeutic effect on CXCL12 causing diseases by countering the effects of CxCL12.
Mode of binding of the cyclic agonist peptide TC14012 to CXCR7: identification of receptor and compound determinants.
TLDR
The results show that the opposite effect of TC14012 on CXCR4 and CxCR7 is not explained by different binding modes, and engagement of the interface between transmembrane domains and extracellular loops readily triggers CXcr7, but not CX CR4, activation.
Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands
TLDR
Results indicate that CX CR7 can regulate CXCL12-mediated migratory cues, and thus may play a critical role in driving CXCR4+CXCR7+ tumor cell metastasis and tissue invasion.
CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
TLDR
The finding that CXCR7 specifically scavenges CXCL12 suggests a critical function of the receptor in modulating the activity of the ubiquitously expressed CX CR4 in development and tumor formation.
Ubiquitination of CXCR7 Controls Receptor Trafficking
TLDR
CXCR7 internalizes and recycles back to the cell surface after agonist exposure, and that internalization is not only β-arrestin-mediated but also dependent on the Serine/Threonine residues at the C-terminus of the receptor, which describes, for the first time, the constitutive ubiquitination of CX CR7.
CXCR4 Antagonists
TLDR
A panel of CXCR4 screening assays investigating Gαi-mediated cyclic adenosine monophosphate modulation, β-arrestin recruitment, and receptor internalization identified several compounds showing a pathway-selective activity and induce different functional states on CX CR4 and preferentially affect specific downstream responses from the activated receptor, thus providing an improved therapeutic profile for correction of CxCR4 abnormal signaling.
Imaging ligand-dependent activation of CXCR7.
TLDR
Ligand-dependent interactions of CXCR7 with beta-arrestin 2 that promote accumulation of chemokines and establish an imaging assay for the dynamic regulation of CxCR7 by chemokine and candidate therapeutic agents in cell-based assays and living mice are demonstrated.
Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
TLDR
It is shown that the previously identified peptides only minimally activated CXCR4 signaling through the cytosolic adapter protein β-arrestin 2 and do not initiate signaling to ERK1/2, and structural information is provided to target allosteric binding sites on this receptor as chemical probes and potential therapeutic agents.
New dimensions in CXCR 4 and Rac 1 regulation
Activation of CXCR4 by its ligand CXCL12 is associated with the migration and/or proliferation of many cell types, including leukocytes, hematopoietic stem cells (HSCs) and tumor cells. Ligand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4
TLDR
It is shown that specific small‐molecule CXCR4 antagonists such as AMD3100 may play an important role in the treatment of human immunodeficiency virus infections and many other pathological processes that are dependent on SDF‐1/CX CR4 interactions.
Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
TLDR
It is demonstrated that AMD3100 is a specific antagonist of CXCR4, is not cross-reactive with other chemokine receptors, and is not an agonist of C XCR4.
Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor
TLDR
It is suggested that non-peptide antagonists with, for example, improved oral bioavailability can be designed to mimic this interaction and thereby efficiently and selectively block the CXCR4 receptor.
Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor*
TLDR
It is concluded that AMD3100 acts on the CXCR4 receptor through binding to Asp171 inTM-IV and Asp262 in TM-VI with each of its cyclam moieties, and it is suggested that part of its function is associated with a conformational constraint imposed upon the receptor by the connecting phenylenebismethylene linker.
CXCR7, CXCR4 and CXCL12: An eccentric trio?
TLDR
The observations do not exclude the possibility that the receptor is capable of inducing signal transduction which is suggestive from studies of tumor growth and survival, and the pronounced expression in central and peripheral nervous tissue and the absence of a brain phenotype in CXCR7(-/-) mice suggest a subtle activity of the receptor.
The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes*
TLDR
It is demonstrated that RDC1 is expressed in T lymphocytes and that CXCL12-promoted chemotaxis is inhibited by an anti-RDC1 monoclonal antibody, and it is shown that CxCL12, the only known natural ligand for CXCR4, binds to and signals through R DC1.
Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists.
TLDR
Results provide pharmacological evidence for the recently described two-site model for SDF-1alpha-CXCR4 interaction, whereby inhibition of SDF -1alpha binding to one of the receptor sites is sufficient to antagonize function, without causing its complete displacement from the receptor.
Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding*
TLDR
It is concluded that a small molecule agonist through binding deep in the main ligand binding pocket can act as an allosteric enhancer for one endogenous Chemokine and at the same time as a competitive blocker of the binding of another endogenous chemokine.
Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100
TLDR
AMD3100 was found to interfere with a number of (patho)physiological processes which depend on the interaction of CXCR4 with its natural ligand, stromal derived factor (SDF-1) and which play an important role in rheumatoid, allergic and malignant diseases.
A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists*
TLDR
Analysis of antagonists revealed that exposure to AMD3100 or ALX40-4C induced G protein activation by CXCR4 wild type, which was greater in the CAM, whereas T140 decreased autonomous signaling, illustrating the importance of transmembrane helix 3 in CX CR4 signaling.
...
1
2
3
4
...